Therapeutic alternatives in cutaneous T-cell lymphoma

J Am Acad Dermatol. 1992 Sep;27(3):367-78. doi: 10.1016/0190-9622(92)70202-q.

Abstract

Mycosis fungoides and Sézary syndrome, collectively referred to as cutaneous T-cell lymphoma, are non-Hodgkin's lymphomas that initially appear in the skin. Early-stage disease, limited to the skin, is best treated with sequential topical therapies such as topical nitrogen mustard, psoralen phototherapy (PUVA), or total-skin electron beam therapy. Photopheresis is the first line of therapy for the patient with erythroderma. Systemic therapy is generally reserved for patients with refractory disease and patients who initially present with extracutaneous involvement. Although there are several treatment options for cutaneous T-cell lymphoma, there have been few randomized comparative trials.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Combined Modality Therapy
  • Humans
  • Interferons / therapeutic use
  • Lymphoma, T-Cell, Cutaneous / drug therapy
  • Lymphoma, T-Cell, Cutaneous / pathology
  • Lymphoma, T-Cell, Cutaneous / radiotherapy
  • Lymphoma, T-Cell, Cutaneous / therapy*
  • Mechlorethamine / therapeutic use
  • Neoplasm Staging
  • PUVA Therapy
  • Photochemotherapy
  • Retinoids / therapeutic use
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / pathology
  • Skin Neoplasms / radiotherapy
  • Skin Neoplasms / therapy*

Substances

  • Retinoids
  • Mechlorethamine
  • Interferons